Network-based in silico drug efficacy screening

Nature Communications

Volumn 7, Issue , 2016, Pages

  Guney, Emre ^a,b   Menche, Jörg ^a,c   Vidal, Marc ^b,d   Barábasi, Albert László ^a,b,c,e  

^a NORTHEASTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CENTRAL EUROPEAN UNIVERSITY   (Hungary)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENTIROMIDE; CHLORPROPAMIDE; DISOPYRAMIDE; DOFETILIDE; ENALAPRIL; FENOFIBRATE; FLECAINIDE; FUROSEMIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; INSULIN ASPART; INSULIN LISPRO; IRBESARTAN; ISOPRENALINE; KETOPROFEN; LIRAGLUTIDE; LOSARTAN; MIGLITOL; MORACIZINE; NATEGLINIDE; PROPAFENONE; RETINOL; SITAGLIPTIN; SOTALOL; SPIRONOLACTONE; TOLAZAMIDE; TOLBUTAMIDE; TOLVAPTAN; UNINDEXED DRUG;

DISEASE INCIDENCE; DRUG; DRUG DEVELOPMENT; GENE EXPRESSION;

ACUTE MYELOBLASTIC LEUKEMIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ARTHROPATHY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BILIARY CIRRHOSIS; BLOOD CLOTTING DISORDER; BONE DISEASE; BREAST TUMOR; COLLAGEN DISEASE; COLORECTAL TUMOR; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CROHN DISEASE; DEGENERATION; DISEASE ASSOCIATION; DISEASES; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG REPOSITIONING; DRUG SCREENING; ENDOCRINE DISEASE; EPILEPSY; EYE DISEASE; GASTROENTERITIS; HEAD AND NECK TUMOR; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERINSULINISM; HYPERSENSITIVITY; HYPOPIGMENTATION; INBORN ERROR OF METABOLISM; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTESTINE TUMOR; KERATOSIS; KIDNEY TUMOR; LUNG DISEASE; LYMPHATIC LEUKEMIA; LYMPHOMA; MALABSORPTION; METABOLIC BONE DISEASE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; NEUROENDOCRINE TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PALLIATIVE THERAPY; PARKINSON DISEASE; PARKINSONISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSTATE TUMOR; PROTEIN PROTEIN INTERACTION; RETINA MACULOPATHY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; VARICOSIS; ARTIFICIAL NEURAL NETWORK; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; COMPUTER SIMULATION; DRUG DEVELOPMENT; PROCEDURES; STRUCTURE ACTIVITY RELATION;

COMPUTER SIMULATION; DRUG DISCOVERY; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEURAL NETWORKS (COMPUTER); STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84956680067     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10331     Document Type: Article

References (49)

1. Barabási, A.-L., Gulbahce, N., Loscalzo, J. Network medicine: a networkbased approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).
2. Amberger, J., Bocchini, C. A., Scott, A. F., Hamosh, A. McKusick's online mendelian inheritance in man (OMIM). Nucleic Acids Res. 37, D793-D796 (2009).
3. Yildirim, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., Vidal, M. Drug-target network. Nat. Biotechnol. 25, 1119-1126 (2007).
4. Berger, S. I., Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009).
5. Wu, Z., Wang, Y., Chen, L. Network-based drug repositioning. Mol. BioSyst. 9, 1268-1281 (2013).
6. Luo, H. et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 39, W492-W498 (2011).
7. Daminelli, S., Haupt, V. J., Reimann, M., Schroeder, M. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. Integr. Biol. 4, 778-788 (2012).
8. Gottlieb, A., Stein, G. Y., Ruppin, E., Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 7, 496 (2011).
9. Lee, H. S. et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst. Biol. 6, 80 (2012).
10. Zhao, S., Li, S. A co-module approach for elucidating drug-disease associations and revealing their molecular basis. Bioinformatics 28, 955-961 (2012).
11. Guney, E., Garcia-Garcia, J., Oliva, B. GUILDify: a web server for phenotypic characterization of genes through biological data integration and networkbased prioritization algorithms. Bioinformatics 30, 1789-1790 (2014).
12. Menche, J. et al. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
13. Rolland, T. et al. A proteome-scale map of the human interactome network. Cell 159, 1212-1226 (2014).
14. Goh, K. et al. The human disease network. Proc. Natl Acad. Sci. USA 104, 8685 (2007).
15. Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. PNAS 106, 9362-9367 (2009).
16. Knox, C. et al. DrugBank 3.0: a comprehensive resource for omics research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
17. Wei, W.-Q. et al. Development and evaluation of an ensemble resource linking medications to their indications. J. Am. Med. Inform. Assoc. 20, 954-961 (2013).
18. Sartor, M. A. et al. Metab2mesh: annotating compounds with medical subject headings. Bioinformatics 28, 1408-1410 (2012).
19. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
20. Cheng, F. et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8, e1002503 (2012).
21. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
22. Hu, G., Agarwal, P. Human disease-drug network based on genomic expression profiles. PLoS ONE 4, e6536 (2009).
23. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96-77 (2011).
24. Pacini, C. et al. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 29, 132-134 (2013).
25. Cheng, J., Yang, L., Kumar, V., Agarwal, P. Systematic evaluation of connectivity map for disease indications. Genome Med. 6, 1-8 (2014).
26. Arrowsmith, J., Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569-569 (2013).
27. Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 39, D691 (2011).
28. Heneka, M. T. et al. NLRP3 is activated in alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678 (2013).
29. Sims-Robinson, C., Kim, B., Rosko, A., Feldman, E. L. How does diabetes accelerate alzheimer disease pathology. Nat. Rev. Neurol. 6, 551-559 (2010).
30. Hiltunen, M. et al. Increased risk of type 2 diabetes in alzheimer disease. J. Cell. Mol. Med. 16, 1206-1222 (2012).
31. Yarchoan, M., Arnold, S. E. Repurposing diabetes drugs for brain insulin resistance in alzheimer disease. Diabetes 63, 2253-2261 (2014).
32. Newhouse, P. et al. Nicotine treatment of mild cognitive impairment a 6-month double-blind pilot clinical trial. Neurology 78, 91-101 (2012).
33. Schramm, T. K. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 32, 1900-1908 (2011).
34. Kuhn, M. et al. Systematic identification of proteins that elicit drug side effects. Mol. Syst. Biol. 9, 663 (2013).
35. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815 (2013).
36. Mottaz, A., Yip, Y. L., Ruch, P., Veuthey, A.-L. Mapping proteins to disease terminologies: from UniProt to MeSH. BMC Bioinform. 9, S3 (2008).
37. Ramos, E. M. et al. Phenotype-genotype integrator (PheGenI): synthesizing genome-wide association study (GWAS) data with existing genomic resources. Eur. J. Hum. Genet. 22, 144-147 (2014).
38. Matys, V. et al. TRANSFACs: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31, 374-378 (2003).
39. Aranda, B. et al. The IntAct molecular interaction database in 2010. Nucleic Acids Res. 38, D525-D531 (2010).
40. Ceol, A. et al. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res. 38(Database issue): D532-D539 (2009).
41. Stark, C. et al. The BioGRID interaction database: 2011 update. Nucleic Acids Res. 39, D698-D704 (2010).
42. Prasad, T. S. K. et al. Human protein reference database-2009 update. Nucleic Acids Res. 37, D767-D772 (2009).
43. Kanehisa, M. et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354-D357 (2006).
44. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. PNAS 104, 1777-1782 (2007).
45. Ruepp, A. et al. CORUM: the comprehensive resource of mammalian protein complexes. Nucleic Acids Res. 36, D646-D650 (2008).
46. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
47. Vinayagam, A. et al. A directed protein interaction network for investigating intracellular signal transduction. Sci. Signal. 4, rs8-rs8 (2011).
48. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
49. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 16, 1061-1070 (2015).